2 news items
Baxter Reports First-Quarter 2024 Results
BAX
2 May 24
selling, general, and administrative expenses, adjusted research and development expenses, adjusted other operating expense (income), net, adjusted
Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
APTX
BAX
23 Apr 24
a team that aims to transform research and development through understanding complex immune interactions (CellSurf™), discovery of novel human
- Prev
- 1
- Next